RU2679448C2 - Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением - Google Patents

Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением Download PDF

Info

Publication number
RU2679448C2
RU2679448C2 RU2015143993A RU2015143993A RU2679448C2 RU 2679448 C2 RU2679448 C2 RU 2679448C2 RU 2015143993 A RU2015143993 A RU 2015143993A RU 2015143993 A RU2015143993 A RU 2015143993A RU 2679448 C2 RU2679448 C2 RU 2679448C2
Authority
RU
Russia
Prior art keywords
ondansetron
tablet
hypromellose
drug
vomiting
Prior art date
Application number
RU2015143993A
Other languages
English (en)
Russian (ru)
Other versions
RU2015143993A (ru
RU2015143993A3 (enExample
Inventor
Реза Фатхи
Гилеад РАДАЙ
Original Assignee
Редхилл Байофарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2679448(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Редхилл Байофарма Лтд. filed Critical Редхилл Байофарма Лтд.
Publication of RU2015143993A publication Critical patent/RU2015143993A/ru
Publication of RU2015143993A3 publication Critical patent/RU2015143993A3/ru
Application granted granted Critical
Publication of RU2679448C2 publication Critical patent/RU2679448C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2015143993A 2013-03-14 2014-03-14 Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением RU2679448C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782395P 2013-03-14 2013-03-14
US61/782,395 2013-03-14
PCT/IB2014/001633 WO2014181195A2 (en) 2013-03-14 2014-03-14 Antiemetic extended release solid dosage forms

Publications (3)

Publication Number Publication Date
RU2015143993A RU2015143993A (ru) 2017-04-20
RU2015143993A3 RU2015143993A3 (enExample) 2018-03-21
RU2679448C2 true RU2679448C2 (ru) 2019-02-11

Family

ID=51528070

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015143993A RU2679448C2 (ru) 2013-03-14 2014-03-14 Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением

Country Status (19)

Country Link
US (5) US20140271851A1 (enExample)
EP (1) EP2983664B1 (enExample)
JP (1) JP6282676B2 (enExample)
KR (1) KR102270521B1 (enExample)
CN (2) CN105530935A (enExample)
AU (1) AU2014264342B2 (enExample)
BR (1) BR112015022398B1 (enExample)
CA (1) CA2905553C (enExample)
CL (1) CL2015002666A1 (enExample)
ES (1) ES2946985T3 (enExample)
HK (1) HK1223012A1 (enExample)
IL (1) IL241580B (enExample)
MX (1) MX378261B (enExample)
NZ (1) NZ712159A (enExample)
PH (1) PH12015502093B1 (enExample)
RU (1) RU2679448C2 (enExample)
SG (1) SG11201507450TA (enExample)
WO (2) WO2014184662A2 (enExample)
ZA (1) ZA201506961B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818947C1 (ru) * 2023-05-15 2024-05-07 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" Министерства здравоохранения Российской Федерации Способ профилактики и лечения тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378261B (es) 2013-03-14 2025-03-10 Redhill Biopharma Ltd Formas de dosificación sólidas de liberación prolongada antieméticas.
SG11201607511WA (en) 2014-03-11 2016-10-28 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
KR102300335B1 (ko) * 2018-10-19 2021-09-10 주식회사 삼양홀딩스 아프레피탄트의 경구용 조성물
GEAP202516774A (en) * 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053413A2 (en) * 2001-12-10 2003-07-03 Quadrant Drug Delivery Limited Sustained-release compositions
US20080200508A1 (en) * 2004-12-20 2008-08-21 Collegium Pharmaceutical, Inc. Pharmaceutical Compositions For Sleep Disorders
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
US20120128730A1 (en) * 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720353A (en) * 1987-04-14 1988-01-19 Richardson-Vicks Inc. Stable pharmaceutical w/o emulsion composition
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
AU2084801A (en) 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
US20050131045A1 (en) 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
ES2285407T3 (es) 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
JP4674162B2 (ja) 2003-11-14 2011-04-20 千寿製薬株式会社 アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤
RU2382637C2 (ru) * 2004-04-30 2010-02-27 Астеллас Фарма Инк. Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CA2661561C (en) * 2006-08-18 2013-12-24 Evonik Operations Gmbh Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water
CN100584319C (zh) 2006-10-16 2010-01-27 北京科信必成医药科技发展有限公司 群孔释放渗透泵控释片及其制备方法
MX2009004439A (es) 2006-10-25 2009-05-11 Mcneil Ppc Inc Composicion de ibuprofeno.
GB0624087D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
CN101568351B (zh) * 2006-12-22 2012-05-30 3M创新有限公司 控制释放的组合物和方法
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20100196291A1 (en) * 2009-01-30 2010-08-05 Laurence Halimi Personal care sunscreen compositions having reduced eye irritation
EP2403487A2 (en) * 2009-03-04 2012-01-11 Fdc Limited Oral controlled release dosage forms for water soluble drugs
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
EP2515882A2 (en) * 2009-12-22 2012-10-31 Abbot Healthcare Private Limited Controlled release pharmaceutical composition
CA2784587A1 (en) 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
WO2012028922A2 (en) 2010-08-30 2012-03-08 Lupin Limited Controlled release pharmaceutical compositions of milnacipran
MX378261B (es) 2013-03-14 2025-03-10 Redhill Biopharma Ltd Formas de dosificación sólidas de liberación prolongada antieméticas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053413A2 (en) * 2001-12-10 2003-07-03 Quadrant Drug Delivery Limited Sustained-release compositions
US20080200508A1 (en) * 2004-12-20 2008-08-21 Collegium Pharmaceutical, Inc. Pharmaceutical Compositions For Sleep Disorders
RU2427389C2 (ru) * 2009-10-09 2011-08-27 Александр Владимирович Диковский Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей
US20120128730A1 (en) * 2010-11-23 2012-05-24 Nipun Davar Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2818947C1 (ru) * 2023-05-15 2024-05-07 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" Министерства здравоохранения Российской Федерации Способ профилактики и лечения тошноты и рвоты у детей и подростков, получающих высокоэметогенную химиотерапию

Also Published As

Publication number Publication date
WO2014184662A3 (en) 2015-04-02
BR112015022398A8 (pt) 2019-11-26
MX378261B (es) 2025-03-10
MX2015012970A (es) 2016-04-11
ZA201506961B (en) 2017-03-29
US20180028452A1 (en) 2018-02-01
IL241580B (en) 2020-08-31
CN105530935A (zh) 2016-04-27
AU2014264342B2 (en) 2017-05-18
EP2983664A2 (en) 2016-02-17
EP2983664A4 (en) 2017-01-04
KR102270521B1 (ko) 2021-06-30
NZ712159A (en) 2019-12-20
JP2016512493A (ja) 2016-04-28
BR112015022398B1 (pt) 2022-01-11
US20140271887A1 (en) 2014-09-18
PH12015502093B1 (en) 2018-09-26
CL2015002666A1 (es) 2017-02-17
WO2014184662A2 (en) 2014-11-20
US20200330392A1 (en) 2020-10-22
EP2983664B1 (en) 2023-04-19
CA2905553A1 (en) 2014-11-13
US9636305B2 (en) 2017-05-02
RU2015143993A (ru) 2017-04-20
US20170189340A1 (en) 2017-07-06
KR20150127253A (ko) 2015-11-16
PH12015502093A1 (en) 2016-01-18
SG11201507450TA (en) 2015-10-29
ES2946985T3 (es) 2023-07-31
HK1223012A1 (zh) 2017-07-21
CA2905553C (en) 2021-04-06
JP6282676B2 (ja) 2018-02-21
RU2015143993A3 (enExample) 2018-03-21
AU2014264342A1 (en) 2015-10-01
WO2014181195A2 (en) 2014-11-13
CN112274489A (zh) 2021-01-29
BR112015022398A2 (pt) 2017-07-18
US20140271851A1 (en) 2014-09-18
WO2014181195A3 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
CN102387802B (zh) 包含羟考酮和纳洛酮的立即释放药物组合物
CZ20023470A3 (cs) Farmaceutický prostředek
US20200330392A1 (en) Bimodal release ondansetron tablets and methods of treating nausea and vomiting
ZA200409171B (en) Sustained release of guaifenesin combination drugs
JP2021518423A (ja) レナリドミドの経口用コーティング錠剤組成物
CN105338970A (zh) 包含他达拉非和坦洛新的药物胶囊复合制剂
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
RU2706708C2 (ru) Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи
JP2023071921A (ja) 様々な用量のレナリドミドの経口用錠剤組成物
JP2018154586A (ja) 錠剤
CA3069948C (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
WO2024024865A1 (ja) レボドパ持続性製剤
HK40045804A (en) Antiemetic extended release solid dosage forms
Sudha et al. Design, Development and Evaluation of Solifenacin Succinate Tablets
Ashutosh et al. Formulation and evaluation of sustained release matrix tablet of antihypertensive drugs using hydrophobic and hydrophilic matrix polymers
EP3900708A1 (en) Extended-release medical composition containing zaltoprofen
WO2015189807A1 (en) Bi-layer tablet formulations of cyclophosphamide and capecitabine and highly fractionated metronomic administration thereof
JP2016504391A (ja) ロラゼパムの制御放出製剤
TW202224681A (zh) 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物
NZ760868B2 (en) A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin
HK1232432B (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
JP2015061830A (ja) 塩酸アンブロキソールの小型徐放性製剤